

Significance of CXCR4, phosphorylated STAT3 and VEGF-A expression in resected non-small cell lung cancer

MENG WANG, GONG-YAN CHEN, HONG-TAO SONG, XUAN HONG, ZHAO-YANG YANG and GUANG-JIE SUI

Department of Respiratory Medicine, The Third Affiliated Hospital of Harbin Medical University, Harbin, P.R. China

Received December 10, 2010; Accepted March 21, 2011

DOI: 10.3892/etm.2011.235

Abstract. C-X-C chemokine receptor type 4 (CXCR4) plays an important role in determining the metastatic potential of non-small cell lung cancer. In order to elucidate the effect and mechanism of CXCR4 in tumor angiogenesis we evaluated the clinical significance of CXCR4, phosphorylated signal transducer and activator of transcription 3 (P-STAT3), and vascular endothelial growth factor (VEGF) expression in patients with completely resected non-small cell lung cancer (NSCLC). A total of 208 cases of resected NSCLC were collected, and expression of CXCR4, P-STAT3 and VEGF-A in tumor tissue was investigated using immunohistochemistry (IHC). We reviewed the patient clinical records to determine the association of the expression of these proteins with the clinical course of the disease. Expression of CXCR4, P-STAT3 and VEGF-A was detected in 56.3, 46.2 and 51.9% of the samples, respectively. We observed co-expression between CXCR4, P-STAT3 and VEGF-A. Using multivariate analysis, the expression levels of CXCR4 and VEGF-A were identified as independent prognostic factors that affected overall survival. In conclusion, the results of this study suggest that CXCR4, P-STAT3 and VEGF-A expression may play a role in tumor progression and angiogenesis of NSCLC. However, further studies are needed to uncover the detailed mechanism that underlies the role of these proteins in NSCLC.

Introduction

Non-small cell lung cancer (NSCLC) is the most common malignancy in northern China, despite its declining incidence. The estimated overall 5-year survival rate is only 16% (1). A more complete understanding of the molecular mechanism of lung cancer will aid in the development of new treatment

modalities, diagnostic technologies and preventive approaches. Thus, increased numbers of molecular markers need to be investigated in order to clarify the features of NSCLC and to ensure effective treatment.

Recent research indicates that the expression of chemokine receptors plays an important role in determining the metastatic potential of tumor cells (2). C-X-C chemokine receptor type 4 (CXCR4) is functionally expressed on the cell surface of various types of cancer cells and plays a role in the cell proliferation and migration of these cells (3). CXCR4 belongs to the superfamily of seven transmembrane domain heterotrimeric G protein-coupled receptors that are physiologically involved in the migration of various hematopoietic cells to home-specific anatomical sites through local interaction with their specific ligands. CXCR4 is overexpressed in colorectal cancer (4), hepatocellular carcinoma (5), ovarian cancer (6), and renal cell carcinoma (7), and is associated with chemotaxis, invasion, angiogenesis and cell proliferation.

Signal transducer and activator of transcription 3 (STAT3) is a key pathway that regulates metastasis in human cancer cells (8), and persistent activation of STAT3 may lead to oncogenesis by promoting tumor angiogenesis, cell proliferation, and resistance to apoptosis (9). In invasive breast cancer tissue, elevated levels of STAT3 phosphorylation were significantly associated with increased expression of downstream targets of STAT3, including inducers of tumor angiogenesis [vascular endothelial growth factor (VEGF), metalloproteinase (MMP)-2, MMP-10 and cyclooxygenase (COX)-2] (10). Tumor growth and development is a complex, multistep process; one essential step for tumor growth is angiogenesis, which plays a critical role in tumor invasion and metastasis (11). VEGF is believed to be the principal growth stimulatory factor for tumor-related angiogenesis. Constitutive activation of STAT3 is able to up-regulate VEGF-A expression in human pancreatic and colorectal cancer cells (12,13).

Therefore, the clinical significance and possible prognostic value of CXCR4, P-STAT3 and VEGF-A expression in patients with completely resected NSCLC was evaluated in the present study to determine the effects of CXCR4 in tumor angiogenesis and metastasis.

Materials and methods

Patients and samples. A total of 208 cases with pathologically confirmed NSCLC were involved in this study. The patients

Correspondence to: Dr Guang-Jie Sui, Department of Respiratory Medicine, The Third Hospital of Harbin Medical University, 150 HaPing Road, Nangang District, Heilongjiang, Harbin 150086, P.R. China
E-mail: suiguangjie88@yahoo.cn

Key words: C-X-C chemokine receptor type 4, phosphorylated signal transducer and activator of transcription 3, vascular endothelial growth factor, immunohistochemistry, prognosis, non-small cell lung cancer




Figure 1. Immunohistochemical expression of (A and B) CXCR4, (C) P-STAT3 and (D) VEGF-A protein in NSCLC tissues (SP method, x200). (A) Immunoreactivity was observed in the cytoplasm of the malignant cells. Brown granules in the cytoplasm of the NSCLC cells indicate CXCR4 protein. (B) Nuclear staining of CXCR4 protein in the NSCLC tissues, and (C) nuclear staining of P-STAT3 protein in the NSCLC tissues. (D) Brown granules in the cytoplasm of the NSCLC cells indicate VEGF-A expression.

underwent potentially curative tumor resection at the Tumor Hospital of Harbin Medical University from 2002 to 2004. The patients received neither chemotherapy nor radiation therapy prior to surgery. Routinely processed formalin-fixed, paraffin-embedded blocks containing principal tumors were selected for the study. Serial sections (4 μ m) were prepared from the cut surface of the blocks at the maximum cross-sectional location of the tumor. Informed consent was obtained from all patients. The study was approved by the Ethics Committee of the Harbin Medical University.

Immunohistochemistry. Immunohistochemical staining for the CXCR4, P-STAT3 and VEGF-A antigen was performed using the standard streptavidin-peroxidase biotin technique (SP technique) with a SP kit (Zhongshan Co., Beijing, China). Paraffin sections (4 μ m) were deparaffinized in xylene and then rehydrated through graded alcohol. Hydrated autoclave pretreatment was carried out by boiling for 5 min in citrate buffer (10 mM, pH 6.0). After endogenous peroxidase was quenched in 3% hydrogen peroxide and blocked for 10 min, the sections were incubated overnight at 4°C with antibodies against CXCR4 (R&D Systems) at a 1:200 dilution, P-STAT3 (Cell Signalling Technology) at a 1:150 dilution and VEGF-A (Neomarkers) at a 1:200 dilution. Biotinylated immunoglobulin and streptavidin conjugated to peroxidase were then added. Finally, 3,3'-diaminobenzidine was added for color development, and hematoxylin was used for counterstaining. Negative control slides processed without the primary antibody were included for each staining. The mean percentage of positive tumor cells was determined in at least five areas at x200 magnification. All slides were evaluated by experienced pathologists who reviewed the slides

together and reached a consensus. Positive expression for P-STAT3 was defined as >25% nuclear staining with greater than moderate staining intensity of tumor cells. The staining of both CXCR4 and VEGF-A was mainly localized in the cytoplasm. CXCR4 and VEGF were scaled as follows: 0, <5%; 1, 5-25%; 2, 25-50%; 3, 50-75%; and 4, >75% positively stained cells. The intensity of immunostaining was scored as follows: 0, none; 1+, weak; 2+, moderate; 3+, intense. The scores for the percentage of positive tumor cells and staining intensity were multiplied together to achieve a weighted score for each case. Cases with weighted scores 0 or 1 were defined as negative; cases with scores ≥ 2 were defined as positive.

Statistical analysis. All data were analyzed by statistical software (SPSS 13.0 for Windows; SPSS, Inc.). The association between CXCR4, P-STAT3 and VEGF-A expression and clinicopathological parameters was analyzed using the χ^2 test. Correlations among the levels of CXCR4, P-STAT3 and VEGF-A protein in NSCLC tissues were determined using Pearson's correlation coefficient (r) analysis. The survival curves were plotted according to the Kaplan-Meier method and validated by the log-rank test. Univariate and multivariate regression analyses were performed using the Cox proportional hazards regression model to analyze the independent factors related to prognosis. For all of the tests, $P < 0.05$ was considered to be statistically significant.

Results

Patient characteristics. Data from a total of 208 patients, 128 male and 80 female, were analyzed. The clinicopatho-

Table I. Correlation between expression of CXCR4, P-STAT3 and VEGF-A and clinicopathological features.

Features	CXCR4				P-STAT3			VEGF-A		
	All patients (n=208)	Negative (n=91)	Positive (n=117)	P-value	Negative (n=112)	Positive (n=96)	P-value	Negative (n=100)	Positive (n=108)	P-value
Age (years)										
<60	89	37	52	0.584	51	38	0.387	48	41	0.144
≥60	119	54	65		61	58		52	67	
Gender										
Male	128	54	74	0.566	67	61	0.582	59	69	0.469
Female	80	37	43		45	35		41	39	
Smoking										
Never	106	47	59	0.859	62	44	0.320	53	53	0.360
Former	81	36	45		41	40		40	41	
Current	21	8	13		9	12		7	14	
Stage										
I	88	54	34	0.000	52	36	0.231	52	36	0.004
II	70	32	38		38	32		33	37	
III	50	5	45		22	28		15	35	
Tumor classification										
T1	83	49	34	0.000	53	30	0.090	48	35	0.002
T2	73	31	42		37	36		39	34	
T3	41	8	33		17	24		10	31	
T4	11	3	8		5	6		3	8	
Lymph node status										
N0	66	38	28	0.011	44	22	0.016	43	23	0.003
N1	101	41	60		52	49		39	62	
N2	41	12	29		16	25		18	23	
Tumor size										
<2 cm	71	43	28	0.001	37	34	0.935	37	34	0.462
2-5 cm	113	42	71		62	51		54	59	
>5 cm	24	6	18		13	11		9	15	
Histology										
Squamous-cell carcinoma	106	50	56	0.241	54	52	0.689	49	57	0.714
Adenocarcinoma	90	34	56		51	39		44	46	
Large-cell carcinoma	12	7	5		7	5		7	5	
Pathological stage										
G1	41	20	21	0.449	27	14	0.198	23	18	0.518
G2	91	42	49		48	43		42	49	
G3	76	29	47		37	39		35	41	

logic features are summarized in Table I. The mean age of the patients was 59.8 years (range, 35-76). There were 106 patients who had never been smokers (50.1%). Pathological tumor stage determined according to the American Joint Committee on Cancer classification included 88 (42.3%) stage I, 70 (33.7%) stage II and 50 (24%) stage III cases. Of the total cases, 106 tumors were squamous, 90 were adenocarcinoma and 12 were large-cell carcinomas. Among the patients with stage III disease, 41 (82%) had lymph node-positive (N2) disease, and the remaining patients had T4 or T3 tumors. The median follow-up was 67 months (range, 1-78.2), the median

disease-free survival was 32.6 months (95% confidence interval, 12-53.2 months), and the median overall survival was 46.2 months. There were 76 patients who had died by the time of the current analysis, with the most common cause of death being disease progression (57 patients).

Expression of CXCR4, P-STAT3 and VEGF in NSCLC. The staining of CXCR4 and VEGF-A was observed predominantly in the cytoplasm of the tumor cells, whereas staining for P-STAT3 appeared in the tumor cell nucleus. Representative immunohistochemical staining of CXCR4, P-STAT3 and




Figure 2. Overall survival curves for patients with resected NSCLC according to the expression levels of CXCR4, P-STAT3 and VEGF-A. (A) The overall survival time of patients with CXCR4-positive cancers was significantly lower compared with the survival time of patients with CXCR4-negative cancers ($P<0.05$). (B) The overall survival time of patients with P-STAT3-positive cancers was significantly lower compared with the survival time of patients with P-STAT3-negative cancers ($P<0.05$). (C) The overall survival time of patients with VEGF-A-positive cancers was significantly lower compared with the survival time of patients with VEGF-A-negative cancers ($P<0.05$).

VEGF-A are provided in Fig. 1. Expression of CXCR4, P-STAT3 and VEGF-A was detected in 117 (56.3%) samples, 96 (46.2%) samples, and 108 (51.9%) samples, respectively. A correlation was noted between P-STAT3 and CXCR4 ($r=0.136$, $P=0.050$), P-STAT3 and VEGF-A ($r=0.231$, $P=0.001$) and CXCR4 and VEGF-A ($r=0.165$, $P=0.017$) (Table II).

Relationship between protein expression and clinical parameters. The relationship between CXCR4, P-STAT3 and VEGF-A expression and clinicopathological features of NSCLC is shown in Table I. Statistical analyses were performed to examine the relationship between the expression of CXCR4 and the clinicopathological features of NSCLC. CXCR4 was found to be significantly correlated with tumor classification, lymph node metastasis, stage and tumor size ($P<0.05$). The expression of P-STAT3 was significantly associated with lymph node metastasis ($P<0.05$). Moreover, a weak association was found between P-STAT3 and tumor classification ($P=0.09$). The expression of VEGF-A was significantly correlated with stage, tumor classification and lymph node metastasis ($P<0.05$).

Overall survival for patients with resected NSCLC according to expression levels of CXCR4, P-STAT3 and VEGF-A. The overall survival time of patients with CXCR4-, P-STAT3- and

VEGF-A-positive cancers was significantly lower compared with the survival time of patients with CXCR4-, P-STAT3- and VEGF-A-negative cancers (all $P<0.05$) (Fig. 2).

Univariate and multivariate analyses of prognostic factors for survival of the NSCLC patients. Univariate analysis showed that smoking, tumor size, lymph node status, stage, tumor classification, pathological stage, CXCR4, P-STAT3 and VEGF expression were significantly correlated with overall patient survival. We carried out multivariate survival analysis as described in statistical analysis. The findings further revealed that tumor size, lymph node metastasis, tumor classification, stage, CXCR4 and VEGF expression were identified as independent predictive factors (Table III).

Discussion

Chemokines, produced by cancer-associated fibroblasts, a component of stromal cells, influence the metastatic potential and site-specific dissemination of cancer cells (14). Endogenous CXCR4 expression on carcinoma cells is known to correlate with a poor prognosis for several carcinoma types (15-17). The knockdown of CXCR4 expression by small interfering RNA in breast carcinoma cells decreases cell invasion and adhesion *in vitro* and abrogates tumor growth *in vivo* (18).

Table II. Correlations between CXCR4, P-STAT3 and VEGF-A expression in the NSCLC tissues.

	P-STAT3				VEGF-A			
	Negative expression	Positive expression	r	P-value	Negative expression	Positive expression	r	P-value
CXCR4								
Negative expression	56	35	0.136	0.050	54	37	0.165	0.017
Positive expression	56	61			50	67		
VEGF								
Negative expression	68	36	0.231	0.001				
Positive expression	44	60						

Table III. Univariate and multivariate analyses of prognostic factors for survival of the NSCLC patients.

Variables	Univariate analysis			Multivariate analysis		
	HR	95% CI	P-value	HR	95% CI	P-value
Age (<60 vs. ≥60 years)	1.151	0.807-1.642	0.438	1.162	0.802-1.683	0.427
Tumor size (<2 vs. ≥2 cm)	2.076	1.386-3.110	0.000	1.638	1.074-2.498	0.022
Smoking (never vs. former, current)	1.497	1.055-2.125	0.024	1.073	0.748-1.537	0.703
Lymph node status (N0 vs. N1, N2)	3.782	2.474-5.781	0.000	2.341	1.684-3.255	0.000
Stage (I vs. II, III)	3.217	2.368-4.372	0.000	2.275	1.636-3.162	0.000
Tumor classification (T1, T2, vs. T4, T3)	3.572	2.463-5.180	0.000	1.804	1.172-2.778	0.007
Pathological stage (G1 vs. G2, G3)	1.832	1.146-2.930	0.011	1.397	0.865-2.259	0.172
CXCR4 (negative vs. positive)	3.006	2.049-4.412	0.000	2.070	1.365-3.140	0.001
Phosphorylated STAT3 (negative vs. positive)	1.768	1.240-2.520	0.002	1.290	0.886-1.877	0.184
VEGF (negative vs. positive)	2.330	1.620-3.353	0.000	1.751	1.194-2.567	0.004

HR, hazard ratio; CI, confidence interval.

In small-cell lung cancer (SCLC) cells, CXCR4 antagonists such as plerixafor (AMD3100) and T140 analogues (TN14003/BKT140) disrupt CXCR4-mediated SCLC cell adhesion to stromal cells, thereby sensitizing SCLC cells to cytotoxic drugs, such as etoposide, and antagonizing cell adhesion-mediated drug resistance (19). These findings suggest that CXCR4 may be a potent oncogenic molecule that plays an important role in NSCLC.

Our study was comprised of a sufficiently large number of participants to demonstrate that the CXCR4 protein was expressed with great frequency (56.3%) in 208 NSCLC tissue samples. Furthermore, CXCR4 exhibited a significant positive correlation with tumor classification, lymph node metastasis, stage and tumor size. CXCR4 expression was significantly correlated with P-STAT3 expression, and it was an independent prognostic factor for survival. The results strongly indicate that CXCR4 has the potential to be utilized as a novel biomarker to identify the progression of NSCLC and predict high-risk patients. It should be noted that CXCR4 staining in our series was primarily located in the cytoplasm. However, in six cases it was found exclusively in the nucleus. This phenomenon has also been described by Na *et al* (20), and may represent a functional status of the receptor; however, we cannot reach any conclusion concerning the different localization as there was not a sufficient number of examined events.

STAT3 is constitutively activated by numerous cytokines, growth factors and oncogenic proteins in many types of human cancers, and it participates in the regulation of malignant processes (9,21,22); moreover, it can directly or indirectly regulate genes related to cell proliferation, metastasis and survival (23,24). STAT3 is a key pathway that regulates survival in human NSCLC (25). In glioblastoma stem cells (GSCs), knockdown of STAT3 induces apoptosis and significantly reduces the expression of Bcl-2 and cyclin-D, suggesting that STAT3 is an important target for human GSCs (26). STAT3 is important in the metastatic process, and blockage of activated STAT3 significantly suppresses MMP-2 expression, and brain and lung tumor cell metastasis (27). In the current study 46.2% of the patients expressed P-STAT3, consistent

with previous studies (28,29). We found a significant association between P-STAT3 and lymph node status ($P=0.016$), and a weak association between P-STAT3 and tumor classification ($P=0.090$); this supports the finding that activated STAT3 contributes to the invasion of NSCLC cells. Therefore, activation of STAT3 may play an important role in tumor invasion and nodal metastasis in NSCLC. Moreover, P-STAT3 expression significantly correlated with VEGF expression, but was not identified as an independent prognostic factor for overall survival in the present study.

Angiogenesis, the formation of new tumor-feeding blood vessels from preexisting vasculature, is critical for the development and subsequent growth of human tumors and is a prerequisite for metastasis. VEGF is considered to be the principal vascular growth factor prompting tumor angiogenesis. The expression of VEGF is associated with poor prognosis and increased resistance to therapeutic intervention in several types of neoplasms (11,30). Our study revealed that the overexpression of VEGF-A as determined in the NSCLC tumor tissue samples was significantly correlated with lymph node metastasis, stage and tumor classification. Co-expression was noted between VEGF-A and CXCR4 expression, which is in accordance with a study by Oda *et al* where similar co-expression was reported (17). In the present study, the overexpression of VEGF-A was a poor independent prognostic factor for overall survival.

In the present study, co-expression was found between CXCR4 and P-STAT3, P-STAT3 and VEGF-A, and finally CXCR4 and VEGF-A. CXCR4 expression was observed in 56.3% of the NSCLC samples and was correlated with tumor classification, lymph node metastasis, stage and tumor size. Furthermore, 46.2% of the patients expressed P-STAT3, and a significant association was found between P-STAT3 and lymph node status and a weak association between P-STAT3 and tumor classification. Overexpression of VEGF-A in the NSCLC tumor tissues was significantly correlated with lymph node metastasis, stage and tumor classification. The present study suggests that these proteins may contribute to tumor progression and angiogenesis, and the results also indicate that

CXCR4 may promote metastasis through the STAT3 signaling pathway. Further studies are needed in order to reveal the detailed mechanism that underlies the role that these proteins play in NSCLC.

References

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. *CA Cancer J Clin* 59: 225-249, 2009.
2. Muller A, Homey B, Soto H, *et al*: Involvement of chemokine receptors in breast cancer metastasis. *Nature* 410: 50-56, 2001.
3. Burger JA and Kipps TJ: CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. *Blood* 107: 1761-1767, 2006.
4. Schimanski CC, Schwald S, Simiontonaki N, *et al*: Effect of chemokine receptors CXCR4 and CCR7 on the metastatic behavior of human colorectal cancer. *Clin Cancer Res* 11: 1743-1750, 2005.
5. Schimanski CC, Bahre R, Gockel I, *et al*: Dissemination of hepatocellular carcinoma is mediated via chemokine receptor CXCR4. *Br J Cancer* 95: 210-217, 2006.
6. Jiang YP, Wu XH, Shi B, Wu WX and Yin GR: Expression of chemokine CXCL12 and its receptor CXCR4 in human epithelial ovarian cancer: an independent prognostic factor for tumor progression. *Gynecol Oncol* 103: 226-233, 2006.
7. Wang L, Wang L, Yang B, *et al*: Strong expression of chemokine receptor CXCR4 by renal cell carcinoma cells correlates with metastasis. *Clin Exp Metastasis* 26: 1049-1054, 2009.
8. Devarajan E and Huang S: STAT3 as a central regulator of tumor metastases. *Curr Mol Med* 9: 626-633, 2009.
9. Yu H and Jove R: The STATs of cancer – new molecular targets come of age. *Nat Rev Cancer* 4: 97-105, 2004.
10. Hsieh FC, Cheng G and Lin J: Evaluation of potential Stat3-regulated genes in human breast cancer. *Biochem Biophys Res Commun* 335: 292-299, 2005.
11. Yasumitsu A, Tabata C, Tabata R and Hirayama N: Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma. *J Thorac Oncol* 5: 479-483, 2010.
12. Huang C, Yang G, Jiang T, Huang K, Cao J and Qiu Z: Effects of IL-6 and AG490 on regulation of Stat3 signaling pathway and invasion of human pancreatic cancer cells in vitro. *J Exp Clin Cancer Res* 29: 51, 2010.
13. Cascio S, Ferla R, D'Andrea A, Gerbino A, Bazan V, Surmacz E and Russo A: Expression of angiogenic regulators, VEGF and leptin, is regulated by the EGF/PI3K/STAT3 pathway in colorectal cancer cells. *J Cell Physiol* 221: 189-194, 2009.
14. Balkwill F: Cancer and the chemokine network. *Nat Rev Cancer* 4: 540-550, 2004.
15. Kim J, Takeuchi H, Lam ST, *et al*: Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. *J Clin Oncol* 23: 2744-2753, 2005.
16. Maréchal R, Demetter P, Nagy N, Berton A, Decaestecker C, Polus M, Closset J, Devière J, Salmon I and van Laethem JL: High expression of CXCR4 may predict poor survival in resected pancreatic adenocarcinoma. *Br J Cancer* 100: 1444-1451, 2009.
17. Oda Y, Tateishi N, Matono H, Matsuura S, Yamamoto H, Tamiya S, Yokoyama R, Matsuda S, Iwamoto Y and Tsuneyoshi M: Chemokine receptor CXCR4 expression is correlated with VEGF expression and poor survival in soft-tissue sarcoma. *Int J Cancer* 124: 1852-1859, 2009.
18. Lapteva N, Yang AG, Sanders DE, Strube RW and Chen SY: CXCR4 knockdown by small interfering RNA abrogates breast tumor growth in vivo. *Cancer Gene Ther* 12: 84-89, 2005.
19. Burger JA and Stewart DJ: CXCR4 chemokine receptor antagonists: perspectives in SCLC. *Expert Opin Investig Drugs* 18: 481-490, 2009.
20. Na IK, Scheibenbogen C, Adam C, Stroux A, Ghadjar P, Thiel E, Keilholz U and Coupland SE: Nuclear expression of CXCR4 in tumor cells of non-small cell lung cancer is correlated with lymph node metastasis. *Hum Pathol* 39: 1751-1755, 2008.
21. Bromberg J: Stat proteins and oncogenesis. *J Clin Invest* 109: 1139-1142, 2002.
22. Al Zaid, Siddiquee K and Turkson J: STAT3 as a target for inducing apoptosis in solid and hematological tumors. *Cell Res* 18: 254-267, 2008.
23. Garcia R, Bowman TL, Niu G, *et al*: Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. *Oncogene* 20: 2499-2513, 2001.
24. Barbieri I, Pensa S, Pannellini T, *et al*: Constitutively active Stat3 enhances neu-mediated migration and metastasis in mammary tumors via upregulation of Cten. *Cancer Res* 70: 2558-2567, 2010.
25. Song L, Turkson J, Karras JG, Jove R and Haura EB: Activation of STAT-3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. *Oncogene* 22: 4150-4165, 2003.
26. Li GH, Wei H, Lv SQ, Ji H and Wang DL: Knockdown of STAT3 expression by RNAi suppresses growth and induces apoptosis and differentiation in glioblastoma stem cells. *Int J Oncol* 37: 103-110, 2010.
27. Xie TX, Wei D, Liu M, Gao AC, Ali-Osman F, Sawaya R and Huang S: Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. *Oncogene* 23: 3550-3560, 2004.
28. Qu P, Roberts J, Li Y, *et al*: Stat3 downstream genes serve as biomarkers in human lung carcinomas and chronic obstructive pulmonary disease. *Lung Cancer* 63: 341-347, 2009.
29. Kim HS, Park YH, Lee J, *et al*: Clinical impact of phosphorylated signal transducer and activator of transcription 3, epidermal growth factor receptor, p53, and vascular endothelial growth factor receptor 1 expression in resected adenocarcinoma of lung by using tissue microarray. *Cancer* 116: 676-685, 2010.
30. Dassoulas K, Gazouli M, Theodoropoulos G, *et al*: Vascular endothelial growth factor and endoglin expression in colorectal cancer. *J Cancer Res Clin Oncol* 136: 703-708, 2010.